Pressure BioSciences (OTCQB:PBIO) said Monday it has signed expanded technology license and supply agreements with Target Discovery Inc, giving Target the right to use its patented Pressure Cycling Technology (PCT) platform for a planned entry into the clinical diagnostics testing market.
Life science company Pressure BioSciences'
patented PCT platform uses rapid and repeating cycles of hydrostatic
pressure at controlled temperatures to extract cell components in the
preparation of a biological sample, such as DNA, and proteins from
humans, animals and plants, for further study.
of the company's PCT-based products are endless - from the key $2
billion target market of mass spectrometry, an analytical technique used
to determine the characteristics of molecules, to biomarker discovery,
forensics and counter-bioterrorism, among other uses.
planned commercial diagnostic services will initially target "critical,
unmet needs" in treatment selection guidance for ovarian cancer, the
Until now, Pressure BioSciences' PCT platform has been available on a “research-use-only” basis.
In 2010, the companies announced a collaboration to combine Pressure BioSciences'
PCT platform with Target's proprietary reagents, to allow for the
extraction of membrane protein biomarkers from human tissue.
These biomarkers are typically difficult to extract from tissue in a form suitable for diagnostic testing.
companies said, however, that they believe their "unique" ability to
rapidly extract and recover the commercially useable protein biomarkers
from cell membranes positions them to "exploit this critical class of
membrane proteins as diagnostic biomarkers".
play key biological roles in cancer, in drug resistance, and in viral
infections, yet until now scientists have been virtually unable to use
this important class of biomarkers for diagnostic and prognostic
testing,” said Target's chief scientific officer, Dr. Luke V. Schneider.
CEO of Target, Jeffrey N. Peterson, added: “We are very pleased
with the progress and outcomes achieved in our on-going multi-year
collaboration with PBI.
"We believe that the PCT Platform, in
combination with TDI’s proprietary reagents, provides reliable access to
this important class of protein biomarkers for life sciences R&D.
further believe that variations measured in these protein isoforms are
expected to translate into important commercial applications, and
desperately needed breakthroughs in improved patient care and
Indeed, the first area of application
is in ovarian cancer, where more than 22,000 women are diagnosed each
year in the US. The companies said over two thirds of these new patients
could be helped "dramatically" by the introduction of "reliable
treatment selection guidance diagnostic information."
non-exclusive, worldwide, royalty-bearing license is for the in vitro
diagnostic services testing for the detection of proteins that may be
regarded as biomarkers of ovarian and other cancers.
agreement includes a minimum royalty that is replaced by an annual
royalty once Target achieves a specified minimum level of diagnostic
It also includes a right of first negotiation and
right of first refusal for an exclusive license to sell biomarker
and/or diagnostic assay products, including instruments, software, kits
and consumables, in a specified field of use.
The license continues for the life of Pressure BioSciences PCT patents.
Under the supply agreement, Pressure BioSciences will make available to Target the PCT instruments and consumables at "most favored nation" pricing, it said.
innovative scientific team at TDI has vaulted important anticipated
applications for PCT forward into near-term realities," said CEO of Pressure BioSciences, Richard T. Schumacher.
power and impact of TDI’s isoform-focused technologies and their
promise in opening a new era in personalized medicine diagnostics for
cancer treatment is dramatic and inspiring.
"We are excited that
PBI’s patented PCT Platform will provide the sample-processing
foundation upon which many of TDI’s next generation clinical laboratory
testing services will be based, and we look forward to supporting our
colleagues at TDI with our continued collaboration, and by fulfilling
their expected PCT Platform instrument and consumables needs," he
Palo Alto, California-based Target Discovery is a
privately held company developing the clinical diagnostics. The company
focuses on creating protein isoform diagnostics to better guide
therapeutic choices and lower overall treatment costs for cancer and
is focused on the development and sale of PCT-enhanced sample
preparation systems (instruments and consumables) for mass spectrometry,
biomarker discovery, bio-therapeutics characterization, vaccine
development, soil and plant biology, forensics, histology, and
Earlier this month, the company
said that Ironridge BioPharma would buy $500,000 in shares of Series E
convertible preferred stock of the company, immediately boosting its
Since Pressure BioSciences
began commercial operations in the middle of 2007, it has come a long
way, releasing a number of PCT-based products geared towards the $6
billion sample preparation market, including three pressure-generating
instruments named Barocyclers, a patent-pending sample homogenization
device (The Shredder SG3), five types of single-use processing
containers and six different, application-specific reagent kits.
the company has installed around 200 of its PCT Barocycler instruments
plus required consumables in laboratories. The sample preparation system
has been proven to be safer, more accurate, reproducible, and much
faster than current cell extraction methods - with up to 48 samples able
to be processed from a wide variety of cells and tissues within